Olmos-Alonso et al., suggest Csf1r gene as a drug target for prevention of AD progression and show that Csf1r inhibition in transgenic mice APP/PS1 using GW2580, a tyrosine kinase inhibitor, results in blockage of microglia proliferation, change of microglia inflammatory profile to non-inflammatory phenotype and also improvement in memory and behavioral tasks, and prevention of synapse destruction [64]. Here, APP is linked to Alzheimer disease.